Table 5

Co-expression of Skp2/ER, Skp2/PGR and their prediction for disease-specific survival in patients with soft tissue sarcomas (univariate analysis; log-rank test), All = 193, Men = 81, Women = 112
Co-expression Patients (n) Patients (%) Median survival (months) 5-Year survival (%) P
Skp2 / ER, all
Low/low 66 34 NR 67 0.049
Low/high 39 20 91 59
High/low 35 18 57 44
High/high 30 16 NR 58
Missing 23 12
Skp2 / ER, men
Low/low 33 41 NR 72 0.427
Low/high 16 20 37 50
High/low 11 14 NR 72
High/high 11 14 63 58
Missing 10 12
Skp2 / ER, women
Low/low 33 29 127 61 0.021
Low/high 23 21 91 65
High/low 24 21 31 32
High/high 19 17 NR 58
Missing 13 12
Skp2 / PGR, all
Low/low 80 41 NR 71 0.056
Low/high 25 13 54 46
High/low 40 21 59 49
High/high 27 14 67 51
Missing 21 11
Skp2 / PGR, men
Low/low 41 51 NR 73 0.141
Low/high 7 9 26 29
High/low 18 22 NR 61
High/high 5 6 67 60
Missing 10 12
Skp2 / PGR, women
Low/low 39 35 NR 68 0.234
Low/high 18 16 75 54
High/low 22 20 29 39
High/high 22 20 57 49
Missing 11 10

Abbreviations: NR, not reached.

Sorbye et al.

Sorbye et al. BMC Clinical Pathology 2013 13:9   doi:10.1186/1472-6890-13-9

Open Data